NCT05150717

ADME Study of [14C]-Jaktinib in Healthy Male Subjects

Absorption, Distribution, Metabolism, and Excretion Study of [14C]-Jaktinib in Chinese Male Healthy Subjects(The Mass Balance and Biotransformation Study of [14C]-Jaktinib).

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Industry
• Sex: Male
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

This study was designed to evaluate the mass balance and biotransformation after single-dose of \[14C\]-Jaktinib orally in Chinese healthy male subjects.

Conditions

• Healthy Adult Male Volunteers

Interventions

Type	Name	Description
DRUG	[14C]-Jaktinib	Subjects will receive single dose of orally \[14C\]-Jaktinib on Day 1.

Timeline

• Start date: 2022-01-04
• Primary completion: 2022-01-30
• Completion: 2022-01-30
• First posted: 2021-12-09
• Last updated: 2024-01-11

Locations

1 site across 1 country: China